Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT00303914
Official study title

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

Study summary

RATIONALE: Questionnaires that assess symptoms caused by cancer and cancer therapy may help improve the ability to plan treatment for patients with invasive cancer to help them live longer and more comfortably. PURPOSE: This clinical trial is studying symptoms caused by cancer and cancer therapy in patients with invasive breast, lung, prostate, or colorectal cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedassessment of therapy complications and cognitive assessment

Plus 1 other study approaches.

Who it may be forBreast Cancer · Cognitive/Functional Effects

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 18, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?32 U.S. locations

Locations may change over time.

Who runs it?Eastern Cooperative Oncology Group

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Eastern Cooperative Oncology Group
Interventions being studied
Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: psychosocial assessment and care
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • DISEASE CHARACTERISTICS:
  • Being seen in an outpatient setting at an ECOG-affiliated academic institution, a CGOP site, or a CCOP site
  • In pretreatment, active treatment, or follow-up for their cancer
  • Clinically diagnosed invasive cancer involving at least 1 of the following primary sites:
  • Breast
  • Lung
  • Prostate
  • Colorectal
  • Hormone receptor status not specified PATIENT CHARACTERISTICS:
  • Male or female
  • Menopausal status not specified
  • Willing to complete a written survey between day 28 and day 35 after completion of the baseline assessment
  • Able to read, write, and understand English
  • No significantly impaired cognitive status which, in the opinion of the investigator, would hinder ability to provide responses PRIOR CONCURRENT THERAPY:
  • Not specified

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern UniversityChicago, Illinois
  • John H. Stroger, Jr. Hospital of Cook CountyChicago, Illinois
  • Evanston HospitalEvanston, Illinois
  • Elkhart General HospitalElkhart, Indiana
  • Howard Community HospitalKokomo, Indiana
  • Center for Cancer Therapy at LaPorte Hospital and Health ServicesLa Porte, Indiana
  • CCOP - Northern Indiana CR ConsortiumSouth Bend, Indiana
  • Memorial Hospital of South BendSouth Bend, Indiana
  • Saint Joseph Regional Medical CenterSouth Bend, Indiana
  • South Bend ClinicSouth Bend, Indiana
  • McFarland Clinic, PCAmes, Iowa
  • Mercy Cancer Center at Mercy Medical Center - North IowaMason City, Iowa

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 18, 2023. Always confirm current availability with the study team.

View original record ↗